Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on RNAi therapeutics market provides in-depth analysis of segments and sub-segments in the global as well as regional RNAi therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional RNAi therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global RNAi therapeutics market.
RNA interference (RNAi) is an established biological reaction to double-stranded RNA that provides resistance to both endogenous parasite and external pathogenic nucleic acids while also regulating protein-coding gene expression. RNA therapeutics is a fast-increasing class of pharmaceuticals that will accelerate treatments to the clinic, enable customized therapy, and render the label "undruggable" obsolete. To treat disease by silencing the expression of specific genes, RNAi therapeutics is used as it consists of a new class of drug molecules. Three types of RNA interference molecules are often distinguished: short hairpin RNAs (shRNAs), microRNAs (miRNAs), and small interfering RNAs (siRNAs). A wide range of diseases, such as oncology, cardiovascular diseases, respiratory disorders, kidney diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and more are cured by using RNAi therapeutics. These treatments have the potential to have long-lasting impacts on the human body, but their growth has a shorter period. RNA interference (RNAi) treatments target genes that were previously thought to be undruggable to cure certain disorders. Notably, RNAi technology had a big influence on the pharmaceutical industry after winning the Nobel Prize in 2006.
The significant expansion of the RNAi therapeutics market is heavily impacted by increased research and development activities targeted at treating chronic illnesses. Unhealthy lifestyles have led to a notable surge in chronic conditions such as diabetes, cardiovascular issues, cancer, and more. RNAi therapies are a novel medication class that has the potential to revolutionize the treatment of many chronic illnesses. Besides, growing cooperation among drug distribution firms and Contract Research Organizations (CROs) helps to drive the growth of the RNAi therapeutics industry. On June 21, 2021, Arrowhead Pharmaceuticals Inc. and Horizon Therapeutics plc disclosed a global partnership and licensing agreement for ARO-XDH, a formerly hidden discovery-stage investigational RNA interference (RNAi) therapeutic being researched by Arrowhead as a potential remedy for uncontrolled gout. However, complex delivery methods limit the broad application of RNAi therapies. RNAi molecules are unstable, big, and charged, therefore there are multiple hurdles to their distribution. However, technical advancements in delivery technology are expanding the range of clinical applications, which presents a potential opportunity for the RNAi therapeutics market. The number of indications for RNAi therapies has expanded due to technological advancements in delivery technology, including cancer and common disorders with significant clinical requirements. Improved RNAi delivery methods are powerful, efficient, non-toxic, or less immunogenic carriers for developing RNAi agents. Nanoparticles have recently gained popularity as a dependable gene carrier with excellent biocompatibility and biodegradability, further creating an opportunity for the market to grow.
The RNAi therapeutics market is segmented into North America, Europe, Asia Pacific, and the rest of the world. The North America region holds a significant share of the RNAi therapeutics market. The region has experienced increased pharmaceutical investment, which is driving up market demand. Furthermore, demand for RNAi medications is also driven across the region due to the increasing research effort in gene therapy, immunotherapy, and cell therapy. Asia Pacific region is estimated to be the fastest-growing region in the RNAi therapeutics market over the forecasted year. Revenues from markets in the Asia Pacific region are predicted to rise throughout the forecast period due to several reasons, including rising healthcare spending, and rapid adoption of novel technologies. Furthermore, there are important market players operating in the area, therefore demand for RNAi therapies is likely to increase throughout the projection period.
| Report Coverage | Details |
|---|---|
| Market Size in 2022 | USD 11.20 Billion |
| Market Size by 2030 | USD 20.23 Billion |
| Growth Rate from 2023 to 2030 | CAGR of 7.69% |
| Largest Market | North America |
| No. of Pages | 300 |
| Market Drivers |
|
| Market Segmentation | By Type, By Application, By Route of Administration, and By End User |
| Regional Scope | North America, Europe, Asia Pacific, and RoW |
The report on global RNAi therapeutics market covers segments such as type, application, route of administration, and end user. On the basis of type, the sub-markets include small interfering RNA (siRNA), and microRNA (miRNA). On the basis of application, the sub-markets include genetic disorders, oncology, neurodegenerative disorders, infectious diseases, renal diseases, and others. On the basis of route of administration, the sub-markets include intradermal injections, pulmonary delivery, and intravenous injections. On the basis of end user, the sub-markets include diagnostic laboratories, research and academic laboratories, and hospitals.
The report provides profiles of the companies in the market such as Alnylam Pharmaceuticals, Inc., QIAGEN, Olix Pharmaceuticals, Inc., Arbutus Biopharma, Silence Therapeutics, Dicerna Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Quark Software Inc., Phio Pharmaceuticals, and Benitec Biopharma Limited.
The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the RNAi therapeutics market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.
